Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 8/2015

01.08.2015 | Original Article

Myeloid molecular characteristics of human γδ T cells support their acquisition of tumor antigen-presenting capacity

verfasst von: Masato Muto, Muhammad Baghdadi, Ryuji Maekawa, Haruka Wada, Ken-ichiro Seino

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 8/2015

Einloggen, um Zugang zu erhalten

Abstract

Human T cells expressing γδ T cell receptor have a potential to show antigen-presenting cell-like phenotype and function upon their activation. However, the mechanisms that underlie the alterations in human γδ T cells remain largely unclear. In this study, we have investigated the molecular characteristics of human γδ T cells related to their acquisition of antigen-presenting capacity in comparison with activated αβ T cells. We found that activated γδ but not αβ T cells upregulated cell surface expression of a scavenger receptor, CD36, which seemed to be mediated by signaling through mitogen-activated protein kinase and/or NF-κB pathways. Confocal microscopical analysis revealed that activated γδ T cells can phagocytose protein antigens. Activated γδ T cells could induce tumor antigen-specific CD8+ T cells using both apoptotic and live tumor cells as antigen resources. Furthermore, we detected that C/EBPα, a critical transcription factor for the development of myeloid-lineage cells, is expressed much higher in γδ T cells than in αβ T cells. These results unveiled the molecular mechanisms for the elicitation of antigen-presenting functions in γδ T cells and would also help designing new approaches for γδ T cell-mediated human cancer immunotherapy.
Literatur
1.
Zurück zum Zitat Kabelitz D, Wesch D, Pitters E, Zöller M (2004) Potential of human gammadelta T lymphocytes for immunotherapy of cancer. Int J Cancer 112(5):727–732PubMedCrossRef Kabelitz D, Wesch D, Pitters E, Zöller M (2004) Potential of human gammadelta T lymphocytes for immunotherapy of cancer. Int J Cancer 112(5):727–732PubMedCrossRef
2.
Zurück zum Zitat Tanaka Y, Morita CT, Tanaka Y (1995) Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature 375:155–158PubMedCrossRef Tanaka Y, Morita CT, Tanaka Y (1995) Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature 375:155–158PubMedCrossRef
3.
Zurück zum Zitat Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I, Galéa C, Salot S, Saiagh S, Audrain M, Rimbert M, Lafaye-de Micheaux S, Tiollier J, Négrier S (2008) Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 57(11):1599–1609PubMedCrossRef Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I, Galéa C, Salot S, Saiagh S, Audrain M, Rimbert M, Lafaye-de Micheaux S, Tiollier J, Négrier S (2008) Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 57(11):1599–1609PubMedCrossRef
4.
Zurück zum Zitat Kobayashi H, Tanaka Y, Yagi J, Minato N, Tanabe K (2011) Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma. Cancer Immunol Immunother 60(8):1075–1084PubMedCrossRef Kobayashi H, Tanaka Y, Yagi J, Minato N, Tanabe K (2011) Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma. Cancer Immunol Immunother 60(8):1075–1084PubMedCrossRef
5.
Zurück zum Zitat Nicol AJ, Tokuyama H, Mattarollo SR, Hagi T, Suzuki K, Yokokawa K, Nieda M (2011) Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer 105:778–786PubMedCentralPubMedCrossRef Nicol AJ, Tokuyama H, Mattarollo SR, Hagi T, Suzuki K, Yokokawa K, Nieda M (2011) Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer 105:778–786PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Nakajima J, Murakawa T, Fukami T, Goto S, Kaneko T, Yoshida Y, Takamoto S, Kakimi K (2010) A phase I study of adoptive immunotherapy for recurrent non-small-lung cancer patients with autologous gammadelta T cells. Eur J Cardiothorac Surg 37:1191–1197PubMedCrossRef Nakajima J, Murakawa T, Fukami T, Goto S, Kaneko T, Yoshida Y, Takamoto S, Kakimi K (2010) A phase I study of adoptive immunotherapy for recurrent non-small-lung cancer patients with autologous gammadelta T cells. Eur J Cardiothorac Surg 37:1191–1197PubMedCrossRef
7.
Zurück zum Zitat Wada I, Matsushita H, Noji S, Mori K, Yamashita H, Nomura S, Shimizu N, Seto Y, Kakimi K (2014) Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer. Cancer Med 3(2):362–375PubMedCentralPubMedCrossRef Wada I, Matsushita H, Noji S, Mori K, Yamashita H, Nomura S, Shimizu N, Seto Y, Kakimi K (2014) Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer. Cancer Med 3(2):362–375PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Kunzmann V, Bauer E, Wilhelm M (1999) γ/δ T-cell stimulation by pamidronate. N Engl J Med 340:737PubMedCrossRef Kunzmann V, Bauer E, Wilhelm M (1999) γ/δ T-cell stimulation by pamidronate. N Engl J Med 340:737PubMedCrossRef
9.
Zurück zum Zitat Kunzmann V, Bauer E, Feurle J, Weißinger F, Tony H-P, Wilhelm M (2000) Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96:384–392PubMed Kunzmann V, Bauer E, Feurle J, Weißinger F, Tony H-P, Wilhelm M (2000) Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96:384–392PubMed
10.
Zurück zum Zitat Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, Tony HP (2003) Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 102(1):200–206PubMedCrossRef Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, Tony HP (2003) Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 102(1):200–206PubMedCrossRef
11.
Zurück zum Zitat Abe Y, Muto M, Nieda M (2009) Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. Exp Hematol 37:956–968PubMedCrossRef Abe Y, Muto M, Nieda M (2009) Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. Exp Hematol 37:956–968PubMedCrossRef
12.
Zurück zum Zitat Brandes M, Willimann K, Moser B (2005) Professional antigen-presentation function by human gammadelta T cells. Science 309(5732):264–268PubMedCrossRef Brandes M, Willimann K, Moser B (2005) Professional antigen-presentation function by human gammadelta T cells. Science 309(5732):264–268PubMedCrossRef
13.
Zurück zum Zitat Wu Y, Wu W, Wong WM, Ward E, Thrasher AJ, Goldblatt D, Osman M, Digard P, Canaday DH, Gustafsson K (2009) Human gamma delta T cells: a lymphoid lineage cell capable of professional phagocytosis. J Immunol 183(9):5622–5629PubMedCrossRef Wu Y, Wu W, Wong WM, Ward E, Thrasher AJ, Goldblatt D, Osman M, Digard P, Canaday DH, Gustafsson K (2009) Human gamma delta T cells: a lymphoid lineage cell capable of professional phagocytosis. J Immunol 183(9):5622–5629PubMedCrossRef
14.
Zurück zum Zitat Landmeier S, Altvater B, Pscherer S et al (2009) Activated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer. J Immunother 32:310–321PubMedCentralPubMedCrossRef Landmeier S, Altvater B, Pscherer S et al (2009) Activated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer. J Immunother 32:310–321PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Altvater B, Pscherer S, Landmeier S, Kailayangiri S, Savoldo B, Juergens H, Rossig C (2012) Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens. Cancer Immunol Immunother 61:385–396PubMedCrossRef Altvater B, Pscherer S, Landmeier S, Kailayangiri S, Savoldo B, Juergens H, Rossig C (2012) Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens. Cancer Immunol Immunother 61:385–396PubMedCrossRef
16.
Zurück zum Zitat Brandes M, Willimann K, Bioley G, Lévy N, Eberl M, Luo M, Tampé R, Lévy F, Romero P, Moser B (2009) Cross-presenting human γδ T cells induce robust CD8+ αβ T cell responses. Proc Natl Acad Sci USA 106(7):2307–2312PubMedCentralPubMedCrossRef Brandes M, Willimann K, Bioley G, Lévy N, Eberl M, Luo M, Tampé R, Lévy F, Romero P, Moser B (2009) Cross-presenting human γδ T cells induce robust CD8+ αβ T cell responses. Proc Natl Acad Sci USA 106(7):2307–2312PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Himoudi N, Morgenstern DA, Yan M, Vernay B, Saraiva L, Wu Y, Cohen CJ, Gustafsson K, Anderson J (2012) Human γδ T lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cells. J Immunol 188(4):1708–1716PubMedCrossRef Himoudi N, Morgenstern DA, Yan M, Vernay B, Saraiva L, Wu Y, Cohen CJ, Gustafsson K, Anderson J (2012) Human γδ T lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cells. J Immunol 188(4):1708–1716PubMedCrossRef
18.
Zurück zum Zitat Umeshappa CS, Huang H, Xie Y, Wei Y, Mulligan SJ, Deng Y, Xiang J (2009) CD4+ Th-APC with acquired peptide/MHC class I and II complexes stimulate type 1 helper CD4+ and central memory CD8+ T cell responses. J Immunol 182(1):193–206PubMedCrossRef Umeshappa CS, Huang H, Xie Y, Wei Y, Mulligan SJ, Deng Y, Xiang J (2009) CD4+ Th-APC with acquired peptide/MHC class I and II complexes stimulate type 1 helper CD4+ and central memory CD8+ T cell responses. J Immunol 182(1):193–206PubMedCrossRef
19.
Zurück zum Zitat Hao S, Yuan J, Xiang J (2007) Nonspecific CD4+ T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8+ CTL responses and long-term T cell memory. J Leukoc Biol 82(4):829–838PubMedCrossRef Hao S, Yuan J, Xiang J (2007) Nonspecific CD4+ T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8+ CTL responses and long-term T cell memory. J Leukoc Biol 82(4):829–838PubMedCrossRef
20.
Zurück zum Zitat Hollis A, Speri B, Graber M, Berg T (2012) The natural product betulinic acid inhibits C/EBP family transcription factors. ChemBioChem 13(2):302–307PubMedCrossRef Hollis A, Speri B, Graber M, Berg T (2012) The natural product betulinic acid inhibits C/EBP family transcription factors. ChemBioChem 13(2):302–307PubMedCrossRef
21.
Zurück zum Zitat Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, Bhardwaj N (1998) Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 188(7):1359–1368PubMedCentralPubMedCrossRef Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, Bhardwaj N (1998) Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 188(7):1359–1368PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Greenberg ME, Sun M, Zhang R, Febbraio M, Silverstein R, Hazen SL (2006) Oxidized phosphatidylserine-CD36 interactions play an essential role in macrophage-dependent phagocytosis of apoptotic cells. J Exp Med 203(12):2613–2625PubMedCentralPubMedCrossRef Greenberg ME, Sun M, Zhang R, Febbraio M, Silverstein R, Hazen SL (2006) Oxidized phosphatidylserine-CD36 interactions play an essential role in macrophage-dependent phagocytosis of apoptotic cells. J Exp Med 203(12):2613–2625PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat Ardeshna KM, Pizzey AR, Devereux S, Khwaja A (2000) The PI3 kinase, p38 SAP kinase, and NF-kappaB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells. Blood 96(3):1039–1046PubMed Ardeshna KM, Pizzey AR, Devereux S, Khwaja A (2000) The PI3 kinase, p38 SAP kinase, and NF-kappaB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells. Blood 96(3):1039–1046PubMed
24.
Zurück zum Zitat Yoshimura S, Bondeson J, Foxwell BM, Brennan FM, Feldmann M (2001) Effective antigen presentation by dendritic cells is NF-kappaB dependent: coordinate regulation of MHC, co-stimulatory molecules and cytokines. Int Immunol 13(5):675–683PubMedCrossRef Yoshimura S, Bondeson J, Foxwell BM, Brennan FM, Feldmann M (2001) Effective antigen presentation by dendritic cells is NF-kappaB dependent: coordinate regulation of MHC, co-stimulatory molecules and cytokines. Int Immunol 13(5):675–683PubMedCrossRef
25.
Zurück zum Zitat Lubick K, Jutila MA (2006) LTA recognition by bovine gammadelta T cells involves CD36. J Leukoc Biol 79(6):1268–1270PubMedCrossRef Lubick K, Jutila MA (2006) LTA recognition by bovine gammadelta T cells involves CD36. J Leukoc Biol 79(6):1268–1270PubMedCrossRef
26.
Zurück zum Zitat Ross SE, Radomska HS, Wu B, Zhang P, Winnay JN, Bajnok L, Wright WS, Schaufele F, Tenen DG, MacDougald OA (2004) Phosphorylation of C/EBPalpha inhibits granulopoiesis. Mol Cell Biol 24(2):675–686PubMedCentralPubMedCrossRef Ross SE, Radomska HS, Wu B, Zhang P, Winnay JN, Bajnok L, Wright WS, Schaufele F, Tenen DG, MacDougald OA (2004) Phosphorylation of C/EBPalpha inhibits granulopoiesis. Mol Cell Biol 24(2):675–686PubMedCentralPubMedCrossRef
27.
Zurück zum Zitat Qiao L, Zou C, Shao P, Schaack J, Johnson PF, Shao J (2008) Transcriptional regulation of fatty acid translocase/CD36 expression by CCAAT/enhancer-binding protein alpha. J Biol Chem 283(14):8788–8795PubMedCentralPubMedCrossRef Qiao L, Zou C, Shao P, Schaack J, Johnson PF, Shao J (2008) Transcriptional regulation of fatty acid translocase/CD36 expression by CCAAT/enhancer-binding protein alpha. J Biol Chem 283(14):8788–8795PubMedCentralPubMedCrossRef
28.
Zurück zum Zitat Meuter S, Eberl M, Moser B (2010) Prolonged antigen survival and cytosolic export in cross-presenting human gammadelta T cells. Proc Natl Acad Sci USA 107(19):8730–8735PubMedCentralPubMedCrossRef Meuter S, Eberl M, Moser B (2010) Prolonged antigen survival and cytosolic export in cross-presenting human gammadelta T cells. Proc Natl Acad Sci USA 107(19):8730–8735PubMedCentralPubMedCrossRef
Metadaten
Titel
Myeloid molecular characteristics of human γδ T cells support their acquisition of tumor antigen-presenting capacity
verfasst von
Masato Muto
Muhammad Baghdadi
Ryuji Maekawa
Haruka Wada
Ken-ichiro Seino
Publikationsdatum
01.08.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 8/2015
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-015-1700-x

Weitere Artikel der Ausgabe 8/2015

Cancer Immunology, Immunotherapy 8/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.